These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 14755320)
1. Donor lymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and nonmyeloablative allogeneic peripheral stem cell transplantation. Musso M; Porretto F; Crescimanno A; Polizzi V; Scalone R Bone Marrow Transplant; 2004 Apr; 33(7):769-71. PubMed ID: 14755320 [TBL] [Abstract][Full Text] [Related]
2. Successful treatment of acquired pure red cell aplasia (PRCA) by allogeneic peripheral blood stem cell transplantation. Tseng SB; Lin SF; Chang CS; Liu TC; Hsiao HH; Liu YC; Tsai HJ; Chen TP Am J Hematol; 2003 Dec; 74(4):273-5. PubMed ID: 14635209 [TBL] [Abstract][Full Text] [Related]
3. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice. Du B; Li DP; Xu KL; Pan XY Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128 [TBL] [Abstract][Full Text] [Related]
4. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515 [TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
6. Successful treatment of refractory acquired pure red cell aplasia (PRCA) by allogeneic bone marrow transplantation. Müller BU; Tichelli A; Passweg JR; Nissen C; Wodnar-Filipowicz A; Gratwohl A Bone Marrow Transplant; 1999 Jun; 23(11):1205-7. PubMed ID: 10382963 [TBL] [Abstract][Full Text] [Related]
7. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies. Helbig G; Stella-Holowiecka B; Wojnar J; Krawczyk M; Krzemien S; Wojciechowska-Sadus M; Markiewicz M; Wylezol I; Kopera M; Holowiecki J Ann Hematol; 2007 Sep; 86(9):677-83. PubMed ID: 17486341 [TBL] [Abstract][Full Text] [Related]
8. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. Corradini P; Dodero A; Zallio F; Caracciolo D; Casini M; Bregni M; Narni F; Patriarca F; Boccadoro M; Benedetti F; Rambaldi A; Gianni AM; Tarella C J Clin Oncol; 2004 Jun; 22(11):2172-6. PubMed ID: 15169805 [TBL] [Abstract][Full Text] [Related]
9. Impact of nonmyeloablative conditioning regimens on the occurrence of pure red cell aplasia after ABO-incompatible allogeneic haematopoietic stem cell transplantation. Malfuson JV; Amor RB; Bonin P; Rodet M; Boccaccio C; Pautas C; Kuentz M; Cordonnier C; Noizat-Pirenne F; Maury S Vox Sang; 2007 Jan; 92(1):85-9. PubMed ID: 17181595 [TBL] [Abstract][Full Text] [Related]
10. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia. Maschan AA; Skorobogatova EV; Balashov DN; Pashanov ED; Trakhtman PE; Schipitzina IP; Skvortsova YV; Rumiantzev AG Bone Marrow Transplant; 2002 Sep; 30(6):405-7. PubMed ID: 12235527 [TBL] [Abstract][Full Text] [Related]
11. Double allogeneic peripheral blood stem cell transplantation in a 9-year-old patient with relapsed acute lymphoblastic leukemia: case report. Fujii H; Goto H; Watanabe Y; Yamazaki S; Takahashi H; Sekiguchi H; Funabiki T; Ikuta K; Yokota S Pediatr Hematol Oncol; 2004; 21(3):261-5. PubMed ID: 15202165 [TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation. Fang B; Song Y; Li N; Li J; Han Q; Zhao RC Ann Hematol; 2009 Mar; 88(3):261-6. PubMed ID: 18769919 [TBL] [Abstract][Full Text] [Related]
13. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin's disease following autologous stem cell transplantation. Ruiz-Argüelles GJ; López-Martínez B; López-Ariza B Arch Med Res; 2003; 34(3):242-5. PubMed ID: 14567405 [TBL] [Abstract][Full Text] [Related]
14. Autologous del(20q)-positive erythroid progenitor cells, re-emerging after DLI treatment of an MDS patient relapsing after allo-SCT, can provide a normal peripheral red blood cell count. Dykes JH; Lindmark A; Lenhoff S; Winqvist I; Johansson B; Olofsson T; Olsson ML Bone Marrow Transplant; 2004 Mar; 33(5):559-63. PubMed ID: 14716343 [TBL] [Abstract][Full Text] [Related]
15. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia]. Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801 [TBL] [Abstract][Full Text] [Related]
16. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning. Canals C; Muñiz-Díaz E; Martínez C; Martino R; Moreno I; Ramos A; Arilla M; Boto N; Pastoret C; Remacha A; Sierra J; Madoz P Transfusion; 2004 Nov; 44(11):1603-11. PubMed ID: 15504166 [TBL] [Abstract][Full Text] [Related]
17. [Remission induction of refractory diffuse large B-cell lymphoma with allogeneic peripheral blood stem cell transplantation followed by interferon-alpha and donor lymphocyte infusion]. Kawano I; Tsukada J; Toda Y; Ogawa R; Higashi T; Iwashige A; Ota T; Kubota A; Mizobe T; Morimoto H; Machida S; Tanaka Y Rinsho Ketsueki; 2004 Feb; 45(2):155-60. PubMed ID: 15045825 [TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation. Buser AS; Stern M; Bucher C; Arber C; Heim D; Halter J; Meyer-Monard S; Stussi G; Lohri A; Ghielmini M; Tichelli A; Passweg JR; Gratwohl A Bone Marrow Transplant; 2007 Mar; 39(6):335-40. PubMed ID: 17342158 [TBL] [Abstract][Full Text] [Related]